Rob Hooft1. Show Affiliations » 1. Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland. rob.hooft@serono.com
Abstract
Entities: Disease
Mesh: See more » AdultAnimalsAppetite/drug effectsChildCongresses as TopicDiabetes Mellitus, Type 2/drug therapyGlucagon/therapeutic useGlucagon-Like Peptide 1HumansObesity/drug therapyObesity/prevention & controlPeptide Fragments/therapeutic usePeptide YY/pharmacologyPharmacology, Clinical/trendsProtein Precursors/therapeutic useReceptors, Glucocorticoid/antagonists & inhibitors
Substances: See more » Peptide FragmentsProtein PrecursorsReceptors, GlucocorticoidPeptide YYpeptide YY (3-36)Glucagon-Like Peptide 1Glucagon
Year: 2003 PMID: 14693465 DOI: 10.1016/s1359-6446(03)02919-2
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851